Form D · Other
Chirality Biosciences, Inc.
Farmingdale, NY · CIK 0002094367
Offering snapshot reported Oct 29, 2025 · SEC filing
- Reported sold
- $3.11M Offering amount: $4.1M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Oct 17, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 29, 2025 | Initial | $3,105,000 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-562393
Total Offering Amount & Total Amount Sold includes $1,100,000 of Convertible Securities converted on a non-cash basis to Series Pre-Seed 2 Shares.
Source: Form D, filed Oct 29, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Joanna Jennings Eagle | Executive |
| Arielle Gabalski | Director, Executive |
| Robert Kayton | Director |
Issuer details
Industry: Other (See others in industry)
Address:
3 Bioscience Park Drive, Room 508
Farmingdale, NY, 11735
Farmingdale, NY, 11735